Explore Our Biomarker Menu


BAD (total)

Biological or Clinical Significance:

BAD is a member of the BCL-2 family. BCL-2 family members are regulators of the programmed cell death pathways. BAD induces apoptosis by inhibiting antiapoptotic BCL-2-family members – BCL-x, Bcl-2, thereby allowing two other pro-apoptotic proteins, BAK and BAX, to aggregate and induce release of cytochrome c, followed by caspase activation and apoptosis. Proapoptotic activity of BAD is regulated through its phosphorylation. Only the nonphosphorylated BAD heterodimerized with BCL-xl or Bcl-2. Phosphorylated BAD is sequestered in the cytosol by binding to 14-3-3. Under certain stress conditions, BAD is activated by dephosphorylation.



BAD (total)



Experienced Running





Required Sample Volume

Disease State:

MSD Panel:

Speak To A Scientist

    I consent to receive communications (which may include, phone, email, social, and re-targeting ads) from BioAgilytix. I understand I may proactively manage my preferences or opt-out of communications with BioAgilytix at any time using the unsubscribe link provided in all of BioAgilytix’s email communications and can learn more by reading the privacy policy.


    Learn why BioAgilytix is a world-leading authority on immunogenicity studies related to ADA, NAb assay development and validation, isotyping, and more.

    Case Studies

    Learn why we’re a trusted partner to 22 of the top 25 global pharma and biotech companies.